[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336909-105":59,"doc-detail-336909-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","zolbetuximab-plus-chemotherapy-for-locally-advanced-unresectable-or-metastatic-stomach-or-gastroesophageal-junction-cancers-a-plain-language-summary","Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers - a plain language summary","","Plain language summary of two clinical trials (SPOTLIGHT and GLOW) evaluating zolbetuximab added to first-line chemotherapy for patients with CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic stomach or gastroesophageal junction (GEJ) cancers. It explains the rationale for targeting CLDN18.2-positive tumor cells, describes how the studies measured time until tumors grew and time after treatment start, and reports average improvements of 1.4–1.9 months and 2.2–2.7 months versus placebo plus chemotherapy. Guidance clarifies that chemotherapy slows tumor growth and notes key definitions and sources.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/zolbetuximab-plus-chemotherapy-for-locally-advanced-unresectable-or-metastatic-stomach-or-gastroesophageal-junction-cancers-a-plain-language-summary/336909/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/zolbetuximab-plus-chemotherapy-for-locally-advanced-unresectable-or-metastatic-stomach-or-gastroesophageal-junction-cancers-a-plain-language-summary/336909.png","ImageObject",300,407,{"name":92,"@type":93},"Sage","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":19},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What cancer types and biomarkers are covered in this summary?","Question",{"text":112,"@type":113},"The summary covers locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers that are CLDN18.2-positive and HER2-negative.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What did SPOTLIGHT and GLOW test, and how was zolbetuximab used?",{"text":117,"@type":113},"Both trials evaluated adding zolbetuximab to first-line chemotherapy, comparing it to a placebo plus chemotherapy approach.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main results reported for time before tumors grew and after starting treatment?",{"text":121,"@type":113},"On average, zolbetuximab plus chemotherapy led to 1.4–1.9 months longer before tumors grew compared with placebo plus chemotherapy, and 2.2–2.7 months longer after starting the trial.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336909,1790869272,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":19,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},687197207057,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Plain Language Summary of Publication  \nZolbetuximab plus chemotherapy for  \nlocally advanced unresectable or metastatic stomach or gastroesophageal junction cancers:  \na plain language summary  \nKohei Shitara1*, Manish A. Shah2*, Florian Lordick3, Yung-Jue Bang4, David Ilson5, Eric Van Cutsem6, Peter Enzinger7, Sunnie S. Kim8, Samuel J. Klempner9, Diarmuid Moran10, Jung Wook Park10, Pranob Bhattacharya10, Jaffer A. Ajani11†  \n& Rui-Hua Xu12†  \nFull affiliations can be found at the end of the article.  \n*These authors are co-first authors.†These authors are co-senior authors.  \nFirst draft submitted: 3 January 2024; Accepted for publication: 9 April 2024; Published online: 22 May 2024  \nSummary  \nWhat is this summary about?  \nThis is a summary of two articles. The first article is about a clinical trial called SPOTLIGHT and it was published in the medical journal The Lancet in April of 2023. The second article is about a clinical trial called GLOW and it was published in the medical journal Nature Medicine in July of 2023.  \nWhat are the key takeaways?  \nUntil recently, chemotherapy was the first treatment given to people with stomach cancer or gastroesophageal junction (or GEJ) cancer that is locally advanced unresectable or metastatic. When cancer cells have high amounts of the protein CLDN18.2 but do not have high amounts of the protein HER2, the cancer is known as CLDN18.2-positive (or CLDN18.2+) and HER2-negative (or HER2−) . New medicines to treat cancer are being developed. These medicines attach to proteins on cancer cells to help the body recognize and kill cancer cells.  \nThe clinical trials SPOTLIGHT and GLOW included participants with CLDN18.2+ and HER2− stomach or GEJ cancer that was locally advanced unresectable or metastatic. These trials looked at whether adding a medicine called zolbetuximab to chemotherapy as the first treatment for cancer helped people live longer before their tumors grew bigger or new tumors grew, after starting the trial. These studies also looked at whether adding zolbetuximab to chemotherapy helped people live longer after starting the trial.  \nWhat were the main conclusions reported by the researchers?  \nHow to say (double click sound icon to play sound)...  \n• Adenocarcinoma:  \na-duh-no-kaar-suh-NO-muh  \n• Capecitabine:  \nka-puh-SAI-tuh-been  \n• CLDN18.2:  \nCLAW-din ay-TEEN-poynt-TOO • Esophagus: uh-SAA-fuh-guhs  \n• Fluorouracil:  \nflaw-ruh-YUR-uh-sil  \n• Folinic Acid: fuh-LI-nuhk A-suhd • Gastroesophageal:  \nga-strow-uh-saa-fuh-JEE-uhl  \n• HER2: hur-TOO  \n• Immunohistochemistry:  \nih-MUYN-oh-HISS-toh-KEHMihs-tree  \n• Metastatic: meh-tuh-STA-tuhk  \n• Nivolumab: nih-VOL-yoo-mab  \n• Oxaliplatin: aak-SA-lee-pla-tin  \n• Pembrolizumab:  \npem-broh-LIH-zoo-mab  \n• Zolbetuximab:  \nzohl-beh-TUHKS-ih-mab  \nIn SPOTLIGHT and GLOW, on average, participants assigned to zolbetuximab plus chemotherapy lived 1.4 to 1.9 months longer before their tumors grew bigger or new tumors grew, after starting the trial, than participants assigned to a placebo plus chemotherapy. On average, participants assigned to zolbetuximab plus chemotherapy also lived 2.2 to 2.7 months longer, after starting the trial, than participants assigned to a placebo plus chemotherapy. These results suggest that zolbetuximab plus chemotherapy could be a new first treatment for people with CLDN18.2+ and HER2− stomach or GEJ cancer that is locally advanced unresectable or metastatic.  \n10.1080/14796694.2024.2342107 © 2024 The Authors Future Oncol. (2024) 20(26), 1861–1877 ISSN 1744-8301 1861  \nPublished by Informa UK Limited, trading as Taylor & Francis Group For reprints and re-use requests, please contact: [t&freprints@tandf.co. uk](t&freprints@tandf.co. uk)  \nPlain Language Summary of Publication Shitara, Shah, Lordick and co-authors  \nWhere can I find the original article on which this summary is based?  \nThe original article ‘Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced u","cbCaivVHa87kUTMK","https://ap.wps.com/l/cbCaivVHa87kUTMK","pdf",5091829,17,"English","# Summary\n## What is this summary about?\n## What are the key takeaways?\n## Main conclusions\n## Where to find the original articles\n## Purpose and key limitations\n## Glossary of terms","[{\"question\":\"What cancer types and biomarkers are covered in this summary?\",\"answer\":\"The summary covers locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers that are CLDN18.2-positive and HER2-negative.\"},{\"question\":\"What did SPOTLIGHT and GLOW test, and how was zolbetuximab used?\",\"answer\":\"Both trials evaluated adding zolbetuximab to first-line chemotherapy, comparing it to a placebo plus chemotherapy approach.\"},{\"question\":\"What were the main results reported for time before tumors grew and after starting treatment?\",\"answer\":\"On average, zolbetuximab plus chemotherapy led to 1.4–1.9 months longer before tumors grew compared with placebo plus chemotherapy, and 2.2–2.7 months longer after starting the trial.\"}]","Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers - a plain language summary | PDF",1790017032,43]